Showing 3581-3590 of 9456 results for "".
- Brepocitinib Improves Cutaneous Dermatomyositis Outcomes Through 52 Weekshttps://practicaldermatology.com/news/brepocitinib-30-mg-improves-cutaneous-dermatomyositis-outcomes-through-52-weeks/2488228/Once-daily oral brepocitinib 30 mg improved skin disease activity, pruritus, and skin-related quality of life in adults with dermatomyositis as early as 4 weeks, according to results from an analysis of phase data from the 3 VALOR trial. The analysis included data from 241 adults with acti
- Study Finds Racial Variation in Keloid Treatmenthttps://practicaldermatology.com/news/study-finds-racial-variation-in-keloid-treatment/2488178/An electronic health record analysis found differences in how keloids are treated across racial groups. In a Letter to the Editor published in the Journal of Drugs in Dermatology, investigators evaluated treatment patterns among adults with keloids using the TriNetX Research Netwo
- Picosecond Laser Study Links Immediate Whitening to Skin Tissue Responsehttps://practicaldermatology.com/news/picosecond-laser-study-links-immediate-whitening-to-skin-tissue-response/2488179/A new in vivo study offers a closer look at what immediate whitening (IW) may represent at the tissue level following picosecond laser irradiation. Researchers publishing in Lasers in Surgery and Medicine, the study evaluated the relationship among IW, vacuole formation, and melan
- INTerpath-001: Intismeran Plus Pembrolizumab Meets Dual Phase 3 Melanoma Endpointshttps://practicaldermatology.com/news/intismeran-plus-pembrolizumab-meets-dual-phase-3-melanoma-endpoints/2488176/Merck and Moderna reported positive topline results from the phase 3 INTerpath-001 trial evaluating intismeran autogene (V940; mRNA-4157) plus pembrolizumab (Keytruda) as adjuvant therapy for completely resected stage IIB-IV cutaneous melanoma. The individualized mRNA-based neoantigen ther
- Phase 3 Study Shows Sustained Psoriasis Responses With SSGJ-608https://practicaldermatology.com/news/phase-3-study-shows-sustained-psoriasis-responses-with-ssgj-608/2488143/A phase 3 trial of the investigational interleukin (IL)-17A–targeting monoclonal antibody (SSGJ-608) showed high response rates through 52 weeks among adults with moderate-to-severe plaque psoriasis. Investigators for the double-blind, placebo-controlled trial included 458 adults in the sa
- Occupational Exposures Implicated in More Than Half of Chronic Hand Eczema Caseshttps://practicaldermatology.com/news/occupational-exposures-implicated-in-more-than-half-of-chronic-hand-eczema-cases/2488120/A new retrospective study of adults with chronic hand eczema (CHE) found allergic contact dermatitis (ACD) and occupational exposures were common, while most patients improved following diagnosis and treatment recommendations that included allergen avoidance. Investigators evaluated 76 adu
- Monophasic HA Shows Longer-Term Benefit in Nasolabial Fold Correctionhttps://practicaldermatology.com/news/monophasic-ha-shows-longer-term-benefit-in-nasolabial-fold-correction/2488118/A randomized study comparing 2 types of hyaluronic acid (HA) dermal fillers found similar early improvements in moderate-to-severe nasolabial folds (NLFs), with outcomes favoring monophasic HA at 36 weeks. Galinde et al conducted a randomized, controlled, double-blinded, intraindividual st
- D-2570 Shows High PASI Response Rates in Phase 2 Psoriasis Studyhttps://practicaldermatology.com/news/d-2570-shows-high-pasi-response-rates-in-phase-2-psoriasis-study/2488078/A novel oral TYK2 inhibitor produced significantly higher skin clearance rates than placebo in patients with moderate-to-severe plaque psoriasis, according to research published in Journal of the American Academy of Dermatology. D-2570 is a TYK2 inhibitor under development for aut
- Researchers Recommend Refined Trial Design for Pediatric Vitiligo JAK Studieshttps://practicaldermatology.com/news/letter-highlights-trial-design-considerations-in-pediatric-vitiligo/2487858/Correspondence in the Journal of the American Academy of Dermatology asked for caution when interpreting findings from a recent trial evaluating oral Janus kinase (JAK) inhibitors in combination with 308-nm excimer laser th
- Guideline-Based Management Limits Testing and Identifies Risk Factors for Chronic Urticaria in Childrenhttps://practicaldermatology.com/news/guideline-based-management-limits-testing-and-identifies-risk-factors-for-chronic-urticaria-in-children/2487889/Most children presenting with a first episode of acute urticaria (AU) recover with conservative, guideline-based management and require little diagnostic testing, according to a prospective cohort study published in Pediatric Allergy, Immunology, and Pulmonolog